Calidi Biotherapeutics(CLDI)
$0.68-0.01 (-1.32%)
CLDI
Calidi Biotherapeutics financials statements
$0.68
At close:-0.01 (-1.32%)
Want to see CLDI full AI Analyst Report?
Calidi Biotherapeutics (CLDI) Ratios
375 Followers
Calidi Biotherapeutics Ratios
CLDI's free cash flow for Q2 2026 was $-4.35M. For the 2026 fiscal year, CLDI's free cash flow was increased by $5.00K and operating cash flow was $-4.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.59 | 1.08 | 0.42 | 0.02 | 0.11 |
| Quick Ratio | 1.59 | 1.08 | 0.42 | 0.02 | 0.11 |
| Cash Ratio | 1.42 | 1.01 | 0.20 | 0.01 | 0.08 |
| Solvency Ratio | -3.58 | -1.69 | -1.53 | -0.47 | -0.41 |
| Operating Cash Flow Ratio | -5.41 | -2.07 | -2.64 | -0.31 | -0.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -6.20 | -33.44 | -2.44 | -1.55 |
| Net Current Asset Value | $ 1.16M | $ -1.99M | $ -13.95M | $ -52.25M | $ -23.26M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.50 | 0.72 | 2.31 | 1.53 |
| Debt-to-Equity Ratio | 0.68 | 4.59 | -0.88 | -0.12 | -0.23 |
| Debt-to-Capital Ratio | 0.41 | 0.82 | -7.24 | -0.13 | -0.30 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.28 | -0.33 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.36 | 9.25 | -1.22 | -0.05 | -0.15 |
| Debt Service Coverage Ratio | -87.95 | -4.80 | -5.31 | -4.48 | -1.68 |
| Interest Coverage Ratio | -97.78 | -23.34 | -7.73 | -146.38 | -17.07 |
| Debt to Market Cap | 0.12 | 0.41 | 0.12 | 0.06 | 0.02 |
| Interest Debt Per Share | 10.31 | 11.99 | 78.37 | 87.06 | 24.28 |
| Net Debt to EBITDA | 0.17 | 0.13 | -0.21 | -0.22 | -0.32 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | -508.89% | 79.06% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -56128.89% | -2139.42% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -55551.11% | -2104.68% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -51395.56% | -2334.52% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -56480.00% | 756.74% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -56504.44% | -2434.97% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -56504.44% | 754.29% |
| Net Income Per EBT | 99.29% | 99.77% | 100.05% | 100.04% | -321.77% |
| EBT Per EBIT | 99.05% | 101.92% | 100.72% | 109.89% | -32.42% |
| Return on Assets (ROA) | -224.75% | -156.13% | -291.61% | -979.09% | -322.41% |
| Return on Equity (ROE) | -529.56% | -1443.48% | 354.78% | 50.41% | 48.35% |
| Return on Capital Employed (ROCE) | -411.21% | -464.70% | 13611.27% | 57.26% | 46.45% |
| Return on Invested Capital (ROIC) | -314.38% | -238.46% | -1695.44% | 66.36% | 59.94% |
| Return on Tangible Assets | -224.75% | -156.13% | -291.61% | -979.09% | -322.41% |
| Earnings Yield | -395.48% | -241.50% | -120.63% | -29.52% | -3.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.77 | 0.00 | 0.44 | 0.13 | 0.15 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.77 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.13 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | -0.00 | -0.03 |
| Cash Conversion Cycle | -131.54 | 0.00 | -836.07 | -2829.42 | -2422.98 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 131.54 | 0.00 | 836.07 | 2829.42 | 2422.98 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -79.19 | -29.64 | -192.51 | -187.19 | -32.58 |
| Free Cash Flow Per Share | -79.64 | -29.67 | -196.69 | -193.25 | -33.44 |
| Dividend Paid and CapEx Coverage Ratio | -177.44 | -11.67 | -46.12 | -30.87 | -37.74 |
| Capital Expenditure Coverage Ratio | -177.44 | -1230.88 | -46.12 | -30.87 | -37.74 |
| Operating Cash Flow Coverage Ratio | -8.30 | -2.80 | -3.73 | -2.21 | -1.50 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -293.64 | -17.31 |
| Free Cash Flow Yield | -425.42% | -214.97% | -113.82% | -15.84% | -2.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.20 | -0.41 | -0.83 | -3.39 | -25.69 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 1914.43 | 625.63 |
| Price-to-Book (P/B) Ratio | 1.34 | 5.98 | -2.94 | -1.71 | -12.42 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.24 | -0.47 | -0.88 | -6.32 | -35.20 |
| Price-to-Operating Cash Flow Ratio | -0.24 | -0.47 | -0.90 | -6.52 | -36.13 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.01 | 0.02 | 0.00 | 0.04 |
| Enterprise Value Multiple | -0.11 | -0.34 | -1.22 | -3.67 | -30.05 |
| Enterprise Value | 2.00M | 6.61M | 29.41M | 91.77M | 283.95M |
| EV to EBITDA | -0.11 | -0.34 | -1.22 | -3.67 | -30.05 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 2039.23 | 632.41 |
| EV to Free Cash Flow | -0.09 | -0.34 | -1.07 | -6.73 | -35.58 |
| EV to Operating Cash Flow | -0.09 | -0.34 | -1.09 | -6.94 | -36.53 |
| Tangible Book Value Per Share | 13.98 | 2.96 | -58.75 | -714.54 | -94.76 |
| Shareholders’ Equity Per Share | 13.98 | 2.31 | -58.75 | -714.54 | -94.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.64 | 1.88 |
| Net Income Per Share | -74.03 | -33.33 | -208.44 | -360.20 | -45.82 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 1.00 | -3.22 |
| Interest Burden | 1.01 | 1.04 | 1.15 | 1.01 | -0.35 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 161.27 | 10.41 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 353.38 | 13.73 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.96 |
| Income Quality | 1.06 | 0.89 | 0.92 | 0.52 | 0.71 |
Currency in USD
